The Enigmatic Role of TP53 in Germ Cell Tumours: Are We Missing Something?

Autor: Ottaviano M; Oncology Unit, Ospedale del Mare, 80147 Naples, Italy.; CRCTR Coordinating Rare Tumors Reference Center of Campania Region, 80131 Naples, Italy.; IOSI (Oncology Institute of Southern Switzerland), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland., Giunta EF; Oncology Unit, Department of Precision Medicine, Università Degli Studi Della Campania Luigi Vanvitelli, 80131 Naples, Italy., Rescigno P; Interdisciplinary Group for Translational Research and Clinical Trials, Urological Cancers (GIRT-Uro), Candiolo Cancer Institute, FPO-IRCCS, Candiolo, 10160 Turin, Italy., Pereira Mestre R; IOSI (Oncology Institute of Southern Switzerland), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland., Marandino L; IOSI (Oncology Institute of Southern Switzerland), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland., Tortora M; CRCTR Coordinating Rare Tumors Reference Center of Campania Region, 80131 Naples, Italy., Riccio V; Department of Clinical Medicine and Surgery, Università degli studi di Napoli Federico II, 80131 Naples, Italy., Parola S; Department of Clinical Medicine and Surgery, Università degli studi di Napoli Federico II, 80131 Naples, Italy., Casula M; Institute of Genetics and Biomedical Research (IRGB), National Research Council (CNR), 07100 Sassari, Italy., Paliogiannis P; Departments of Biomedical Sciences and Medical, Surgical, Experimental Sciences, University of Sassari, 07100 Sassari, Italy., Cossu A; Departments of Biomedical Sciences and Medical, Surgical, Experimental Sciences, University of Sassari, 07100 Sassari, Italy., Vogl UM; IOSI (Oncology Institute of Southern Switzerland), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland., Bosso D; Oncology Unit, Ospedale del Mare, 80147 Naples, Italy., Rosanova M; Oncology Unit, Ospedale del Mare, 80147 Naples, Italy., Mazzola B; Department of Urology, Ente Ospedaliero Cantonale (EOC), 6600 Locarno, Switzerland., Daniele B; Oncology Unit, Ospedale del Mare, 80147 Naples, Italy., Palmieri G; Institute of Genetics and Biomedical Research (IRGB), National Research Council (CNR), 07100 Sassari, Italy.; Departments of Biomedical Sciences and Medical, Surgical, Experimental Sciences, University of Sassari, 07100 Sassari, Italy., Palmieri G; CRCTR Coordinating Rare Tumors Reference Center of Campania Region, 80131 Naples, Italy.
Jazyk: angličtina
Zdroj: International journal of molecular sciences [Int J Mol Sci] 2021 Jul 02; Vol. 22 (13). Date of Electronic Publication: 2021 Jul 02.
DOI: 10.3390/ijms22137160
Abstrakt: The cure rate of germ cell tumours (GCTs) has significantly increased from the late 1970s since the introduction of cisplatin-based therapy, which to date remains the milestone for GCTs treatment. The exquisite cisplatin sensitivity has been mainly explained by the over-expression in GCTs of wild-type TP53 protein and the lack of TP53 somatic mutations; however, several other mechanisms seem to be involved, many of which remain still elusive. The findings about the role of TP53 in platinum-sensitivity and resistance, as well as the reported evidence of second cancers (SCs) in GCT patients treated only with surgery, suggesting a spectrum of cancer predisposing syndromes, highlight the need for a deepened understanding of the role of TP53 in GCTs. In the following report we explore the complex role of TP53 in GCTs cisplatin-sensitivity and resistance mechanisms, passing through several recent genomic studies, as well as its role in GCT patients with SCs, going through our experience of Center of reference for both GCTs and cancer predisposing syndromes.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje